nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—LTK—polycystic ovary syndrome	0.644	0.866	CbGaD
Erlotinib—CYP1A1—polycystic ovary syndrome	0.1	0.135	CbGaD
Erlotinib—UGT1A1—urine—polycystic ovary syndrome	0.00348	0.0337	CbGeAlD
Erlotinib—Vandetanib—FLT4—polycystic ovary syndrome	0.00289	0.451	CrCbGaD
Erlotinib—Vandetanib—LTK—polycystic ovary syndrome	0.0024	0.374	CrCbGaD
Erlotinib—Nail disorder—Metformin—polycystic ovary syndrome	0.00169	0.072	CcSEcCtD
Erlotinib—CYP1A2—urine—polycystic ovary syndrome	0.00154	0.0149	CbGeAlD
Erlotinib—TNK1—endometrium—polycystic ovary syndrome	0.00152	0.0147	CbGeAlD
Erlotinib—JAK3—adipose tissue—polycystic ovary syndrome	0.00149	0.0144	CbGeAlD
Erlotinib—HIPK4—endocrine gland—polycystic ovary syndrome	0.00147	0.0142	CbGeAlD
Erlotinib—NR1I2—endocrine gland—polycystic ovary syndrome	0.00145	0.014	CbGeAlD
Erlotinib—AURKC—adrenal gland—polycystic ovary syndrome	0.00144	0.014	CbGeAlD
Erlotinib—TNK1—uterus—polycystic ovary syndrome	0.0014	0.0136	CbGeAlD
Erlotinib—TNK1—pituitary gland—polycystic ovary syndrome	0.00137	0.0133	CbGeAlD
Erlotinib—Rigors—Metformin—polycystic ovary syndrome	0.00135	0.0572	CcSEcCtD
Erlotinib—JAK3—adrenal gland—polycystic ovary syndrome	0.00134	0.013	CbGeAlD
Erlotinib—PIP4K2C—adrenal cortex—polycystic ovary syndrome	0.00132	0.0128	CbGeAlD
Erlotinib—ULK3—adrenal cortex—polycystic ovary syndrome	0.00126	0.0122	CbGeAlD
Erlotinib—AURKC—endocrine gland—polycystic ovary syndrome	0.00125	0.0121	CbGeAlD
Erlotinib—JAK3—female gonad—polycystic ovary syndrome	0.00125	0.0121	CbGeAlD
Erlotinib—TNK1—adrenal gland—polycystic ovary syndrome	0.00123	0.0119	CbGeAlD
Erlotinib—MKNK1—adrenal cortex—polycystic ovary syndrome	0.00119	0.0115	CbGeAlD
Erlotinib—PIP4K2C—endometrium—polycystic ovary syndrome	0.00118	0.0114	CbGeAlD
Erlotinib—EPHA6—endocrine gland—polycystic ovary syndrome	0.00116	0.0112	CbGeAlD
Erlotinib—JAK3—endocrine gland—polycystic ovary syndrome	0.00116	0.0112	CbGeAlD
Erlotinib—TNK1—female gonad—polycystic ovary syndrome	0.00115	0.0111	CbGeAlD
Erlotinib—TNK1—vagina—polycystic ovary syndrome	0.00114	0.011	CbGeAlD
Erlotinib—ABL2—pituitary gland—polycystic ovary syndrome	0.00113	0.0109	CbGeAlD
Erlotinib—ULK3—endometrium—polycystic ovary syndrome	0.00113	0.0109	CbGeAlD
Erlotinib—SLK—adrenal cortex—polycystic ovary syndrome	0.00112	0.0109	CbGeAlD
Erlotinib—ABL2—adipose tissue—polycystic ovary syndrome	0.00112	0.0109	CbGeAlD
Erlotinib—EGFR—uterus—polycystic ovary syndrome	0.00112	0.0109	CbGeAlD
Erlotinib—CYP3A4—urine—polycystic ovary syndrome	0.00112	0.0108	CbGeAlD
Erlotinib—CYP2D6—urine—polycystic ovary syndrome	0.0011	0.0106	CbGeAlD
Erlotinib—EGFR—adipose tissue—polycystic ovary syndrome	0.0011	0.0106	CbGeAlD
Erlotinib—PIP4K2C—pituitary gland—polycystic ovary syndrome	0.00107	0.0103	CbGeAlD
Erlotinib—TNK1—endocrine gland—polycystic ovary syndrome	0.00106	0.0103	CbGeAlD
Erlotinib—PIP4K2C—adipose tissue—polycystic ovary syndrome	0.00106	0.0103	CbGeAlD
Erlotinib—MKNK1—endometrium—polycystic ovary syndrome	0.00106	0.0103	CbGeAlD
Erlotinib—FLT3—adrenal gland—polycystic ovary syndrome	0.00106	0.0102	CbGeAlD
Erlotinib—ULK3—uterus—polycystic ovary syndrome	0.00104	0.01	CbGeAlD
Erlotinib—Neuropathy—Metformin—polycystic ovary syndrome	0.00103	0.0438	CcSEcCtD
Erlotinib—ULK3—pituitary gland—polycystic ovary syndrome	0.00102	0.00986	CbGeAlD
Erlotinib—ULK3—adipose tissue—polycystic ovary syndrome	0.00101	0.00982	CbGeAlD
Erlotinib—ABL2—adrenal gland—polycystic ovary syndrome	0.00101	0.00975	CbGeAlD
Erlotinib—SLK—endometrium—polycystic ovary syndrome	0.001	0.00971	CbGeAlD
Erlotinib—FLT3—female gonad—polycystic ovary syndrome	0.000984	0.00953	CbGeAlD
Erlotinib—EGFR—adrenal gland—polycystic ovary syndrome	0.000983	0.00952	CbGeAlD
Erlotinib—MKNK1—pituitary gland—polycystic ovary syndrome	0.000959	0.00928	CbGeAlD
Erlotinib—MKNK1—adipose tissue—polycystic ovary syndrome	0.000955	0.00925	CbGeAlD
Erlotinib—PIP4K2C—adrenal gland—polycystic ovary syndrome	0.000953	0.00923	CbGeAlD
Erlotinib—ABL2—female gonad—polycystic ovary syndrome	0.000939	0.00909	CbGeAlD
Erlotinib—ABL2—vagina—polycystic ovary syndrome	0.000934	0.00904	CbGeAlD
Erlotinib—SLK—uterus—polycystic ovary syndrome	0.000925	0.00895	CbGeAlD
Erlotinib—EGFR—female gonad—polycystic ovary syndrome	0.000917	0.00888	CbGeAlD
Erlotinib—FLT3—endocrine gland—polycystic ovary syndrome	0.000915	0.00886	CbGeAlD
Erlotinib—ULK3—adrenal gland—polycystic ovary syndrome	0.00091	0.00881	CbGeAlD
Erlotinib—SLK—pituitary gland—polycystic ovary syndrome	0.000908	0.00879	CbGeAlD
Erlotinib—SLK—adipose tissue—polycystic ovary syndrome	0.000904	0.00876	CbGeAlD
Erlotinib—PIP4K2C—female gonad—polycystic ovary syndrome	0.000889	0.0086	CbGeAlD
Erlotinib—PIP4K2C—vagina—polycystic ovary syndrome	0.000883	0.00855	CbGeAlD
Erlotinib—MAP2K5—adrenal cortex—polycystic ovary syndrome	0.000873	0.00845	CbGeAlD
Erlotinib—MKNK1—adrenal gland—polycystic ovary syndrome	0.000856	0.00829	CbGeAlD
Erlotinib—ULK3—female gonad—polycystic ovary syndrome	0.000849	0.00822	CbGeAlD
Erlotinib—ULK3—vagina—polycystic ovary syndrome	0.000843	0.00817	CbGeAlD
Erlotinib—Renal impairment—Metformin—polycystic ovary syndrome	0.000838	0.0356	CcSEcCtD
Erlotinib—PIP4K2C—endocrine gland—polycystic ovary syndrome	0.000826	0.008	CbGeAlD
Erlotinib—ABL1—embryo—polycystic ovary syndrome	0.000821	0.00795	CbGeAlD
Erlotinib—SLK—adrenal gland—polycystic ovary syndrome	0.000811	0.00785	CbGeAlD
Erlotinib—STK10—uterus—polycystic ovary syndrome	0.000804	0.00778	CbGeAlD
Erlotinib—MKNK1—female gonad—polycystic ovary syndrome	0.000799	0.00773	CbGeAlD
Erlotinib—MKNK1—vagina—polycystic ovary syndrome	0.000794	0.00769	CbGeAlD
Erlotinib—ULK3—endocrine gland—polycystic ovary syndrome	0.000789	0.00764	CbGeAlD
Erlotinib—STK10—adipose tissue—polycystic ovary syndrome	0.000786	0.00761	CbGeAlD
Erlotinib—MAP2K5—endometrium—polycystic ovary syndrome	0.000779	0.00754	CbGeAlD
Erlotinib—Vandetanib—VEGFA—polycystic ovary syndrome	0.000771	0.12	CrCbGaD
Erlotinib—SLK—female gonad—polycystic ovary syndrome	0.000756	0.00732	CbGeAlD
Erlotinib—SLK—vagina—polycystic ovary syndrome	0.000752	0.00728	CbGeAlD
Erlotinib—MKNK1—endocrine gland—polycystic ovary syndrome	0.000743	0.00719	CbGeAlD
Erlotinib—Dehydration—Metformin—polycystic ovary syndrome	0.000741	0.0315	CcSEcCtD
Erlotinib—STK10—adrenal gland—polycystic ovary syndrome	0.000705	0.00683	CbGeAlD
Erlotinib—MAP2K5—pituitary gland—polycystic ovary syndrome	0.000705	0.00683	CbGeAlD
Erlotinib—MAP2K5—adipose tissue—polycystic ovary syndrome	0.000702	0.0068	CbGeAlD
Erlotinib—Pancreatitis—Metformin—polycystic ovary syndrome	0.000675	0.0287	CcSEcCtD
Erlotinib—ABL1—adrenal cortex—polycystic ovary syndrome	0.000673	0.00652	CbGeAlD
Erlotinib—STK10—female gonad—polycystic ovary syndrome	0.000658	0.00637	CbGeAlD
Erlotinib—STK10—vagina—polycystic ovary syndrome	0.000654	0.00633	CbGeAlD
Erlotinib—Neutropenia—Metformin—polycystic ovary syndrome	0.000644	0.0274	CcSEcCtD
Erlotinib—ORM1—endometrium—polycystic ovary syndrome	0.000633	0.00613	CbGeAlD
Erlotinib—MAP2K5—adrenal gland—polycystic ovary syndrome	0.00063	0.0061	CbGeAlD
Erlotinib—Infestation—Metformin—polycystic ovary syndrome	0.000614	0.0261	CcSEcCtD
Erlotinib—Infestation NOS—Metformin—polycystic ovary syndrome	0.000614	0.0261	CcSEcCtD
Erlotinib—STK10—endocrine gland—polycystic ovary syndrome	0.000612	0.00592	CbGeAlD
Erlotinib—Neuropathy peripheral—Metformin—polycystic ovary syndrome	0.000602	0.0256	CcSEcCtD
Erlotinib—ABL1—endometrium—polycystic ovary syndrome	0.000601	0.00582	CbGeAlD
Erlotinib—MAP2K5—female gonad—polycystic ovary syndrome	0.000587	0.00569	CbGeAlD
Erlotinib—MAP2K5—vagina—polycystic ovary syndrome	0.000584	0.00565	CbGeAlD
Erlotinib—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000581	0.0247	CcSEcCtD
Erlotinib—UGT1A1—endocrine gland—polycystic ovary syndrome	0.000578	0.00559	CbGeAlD
Erlotinib—SLCO2B1—uterus—polycystic ovary syndrome	0.000559	0.00541	CbGeAlD
Erlotinib—ABL1—uterus—polycystic ovary syndrome	0.000554	0.00536	CbGeAlD
Erlotinib—Hepatitis—Metformin—polycystic ovary syndrome	0.000551	0.0234	CcSEcCtD
Erlotinib—SLCO2B1—adipose tissue—polycystic ovary syndrome	0.000546	0.00529	CbGeAlD
Erlotinib—MAP2K5—endocrine gland—polycystic ovary syndrome	0.000546	0.00529	CbGeAlD
Erlotinib—ABL1—pituitary gland—polycystic ovary syndrome	0.000544	0.00527	CbGeAlD
Erlotinib—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.000542	0.023	CcSEcCtD
Erlotinib—ABL1—adipose tissue—polycystic ovary syndrome	0.000542	0.00525	CbGeAlD
Erlotinib—Eye disorder—Metformin—polycystic ovary syndrome	0.000515	0.0219	CcSEcCtD
Erlotinib—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000497	0.0211	CcSEcCtD
Erlotinib—Chills—Metformin—polycystic ovary syndrome	0.000495	0.021	CcSEcCtD
Erlotinib—SLCO2B1—adrenal gland—polycystic ovary syndrome	0.00049	0.00475	CbGeAlD
Erlotinib—ABL1—adrenal gland—polycystic ovary syndrome	0.000486	0.0047	CbGeAlD
Erlotinib—Malnutrition—Metformin—polycystic ovary syndrome	0.00048	0.0204	CcSEcCtD
Erlotinib—Erythema—Metformin—polycystic ovary syndrome	0.00048	0.0204	CcSEcCtD
Erlotinib—Flatulence—Metformin—polycystic ovary syndrome	0.000473	0.0201	CcSEcCtD
Erlotinib—CYP1B1—uterus—polycystic ovary syndrome	0.000469	0.00454	CbGeAlD
Erlotinib—CYP1B1—pituitary gland—polycystic ovary syndrome	0.000461	0.00446	CbGeAlD
Erlotinib—CYP1B1—adipose tissue—polycystic ovary syndrome	0.000459	0.00444	CbGeAlD
Erlotinib—SLCO2B1—female gonad—polycystic ovary syndrome	0.000457	0.00443	CbGeAlD
Erlotinib—ABL1—female gonad—polycystic ovary syndrome	0.000453	0.00439	CbGeAlD
Erlotinib—ABL1—vagina—polycystic ovary syndrome	0.00045	0.00436	CbGeAlD
Erlotinib—ALB—adrenal gland—polycystic ovary syndrome	0.000448	0.00434	CbGeAlD
Erlotinib—ORM1—endocrine gland—polycystic ovary syndrome	0.000443	0.00429	CbGeAlD
Erlotinib—Syncope—Metformin—polycystic ovary syndrome	0.00043	0.0183	CcSEcCtD
Erlotinib—SLCO2B1—endocrine gland—polycystic ovary syndrome	0.000425	0.00412	CbGeAlD
Erlotinib—ABCG2—adrenal cortex—polycystic ovary syndrome	0.000424	0.00411	CbGeAlD
Erlotinib—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000422	0.0179	CcSEcCtD
Erlotinib—ABL1—endocrine gland—polycystic ovary syndrome	0.000421	0.00408	CbGeAlD
Erlotinib—CYP1B1—adrenal gland—polycystic ovary syndrome	0.000411	0.00398	CbGeAlD
Erlotinib—Myalgia—Metformin—polycystic ovary syndrome	0.000409	0.0174	CcSEcCtD
Erlotinib—Chest pain—Metformin—polycystic ovary syndrome	0.000409	0.0174	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000406	0.0173	CcSEcCtD
Erlotinib—Oedema—Metformin—polycystic ovary syndrome	0.000392	0.0167	CcSEcCtD
Erlotinib—CYP2C8—endometrium—polycystic ovary syndrome	0.00039	0.00377	CbGeAlD
Erlotinib—Infection—Metformin—polycystic ovary syndrome	0.000389	0.0166	CcSEcCtD
Erlotinib—Shock—Metformin—polycystic ovary syndrome	0.000385	0.0164	CcSEcCtD
Erlotinib—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000384	0.0163	CcSEcCtD
Erlotinib—CYP1B1—female gonad—polycystic ovary syndrome	0.000384	0.00372	CbGeAlD
Erlotinib—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000384	0.0163	CcSEcCtD
Erlotinib—Skin disorder—Metformin—polycystic ovary syndrome	0.000381	0.0162	CcSEcCtD
Erlotinib—ABCG2—endometrium—polycystic ovary syndrome	0.000379	0.00367	CbGeAlD
Erlotinib—Anorexia—Metformin—polycystic ovary syndrome	0.000373	0.0159	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000357	0.0152	CcSEcCtD
Erlotinib—CYP1B1—endocrine gland—polycystic ovary syndrome	0.000357	0.00346	CbGeAlD
Erlotinib—Gefitinib—CYP1A1—polycystic ovary syndrome	0.000354	0.0552	CrCbGaD
Erlotinib—CYP2C8—pituitary gland—polycystic ovary syndrome	0.000353	0.00342	CbGeAlD
Erlotinib—Dyspnoea—Metformin—polycystic ovary syndrome	0.000349	0.0149	CcSEcCtD
Erlotinib—ABCG2—uterus—polycystic ovary syndrome	0.000349	0.00338	CbGeAlD
Erlotinib—Dyspepsia—Metformin—polycystic ovary syndrome	0.000345	0.0147	CcSEcCtD
Erlotinib—ABCG2—pituitary gland—polycystic ovary syndrome	0.000343	0.00332	CbGeAlD
Erlotinib—ABCG2—adipose tissue—polycystic ovary syndrome	0.000342	0.00331	CbGeAlD
Erlotinib—Decreased appetite—Metformin—polycystic ovary syndrome	0.000341	0.0145	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000338	0.0144	CcSEcCtD
Erlotinib—Fatigue—Metformin—polycystic ovary syndrome	0.000338	0.0144	CcSEcCtD
Erlotinib—Constipation—Metformin—polycystic ovary syndrome	0.000335	0.0142	CcSEcCtD
Erlotinib—CYP1A1—uterus—polycystic ovary syndrome	0.000332	0.00321	CbGeAlD
Erlotinib—CYP1A1—adipose tissue—polycystic ovary syndrome	0.000324	0.00314	CbGeAlD
Erlotinib—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.00032	0.0136	CcSEcCtD
Erlotinib—CYP3A5—adipose tissue—polycystic ovary syndrome	0.000317	0.00307	CbGeAlD
Erlotinib—Abdominal pain—Metformin—polycystic ovary syndrome	0.00031	0.0132	CcSEcCtD
Erlotinib—ABCG2—adrenal gland—polycystic ovary syndrome	0.000306	0.00297	CbGeAlD
Erlotinib—CYP2C8—vagina—polycystic ovary syndrome	0.000292	0.00283	CbGeAlD
Erlotinib—ABCG2—female gonad—polycystic ovary syndrome	0.000286	0.00277	CbGeAlD
Erlotinib—ABCG2—vagina—polycystic ovary syndrome	0.000284	0.00275	CbGeAlD
Erlotinib—Asthenia—Metformin—polycystic ovary syndrome	0.000281	0.012	CcSEcCtD
Erlotinib—Pruritus—Metformin—polycystic ovary syndrome	0.000277	0.0118	CcSEcCtD
Erlotinib—CYP2C8—endocrine gland—polycystic ovary syndrome	0.000273	0.00265	CbGeAlD
Erlotinib—CYP1A1—female gonad—polycystic ovary syndrome	0.000271	0.00263	CbGeAlD
Erlotinib—CYP1A1—vagina—polycystic ovary syndrome	0.00027	0.00261	CbGeAlD
Erlotinib—Diarrhoea—Metformin—polycystic ovary syndrome	0.000268	0.0114	CcSEcCtD
Erlotinib—CYP3A5—female gonad—polycystic ovary syndrome	0.000265	0.00257	CbGeAlD
Erlotinib—CYP3A5—vagina—polycystic ovary syndrome	0.000264	0.00255	CbGeAlD
Erlotinib—Dizziness—Metformin—polycystic ovary syndrome	0.000259	0.011	CcSEcCtD
Erlotinib—CYP1A2—endocrine gland—polycystic ovary syndrome	0.000256	0.00248	CbGeAlD
Erlotinib—ABCB1—embryo—polycystic ovary syndrome	0.000255	0.00247	CbGeAlD
Erlotinib—CYP1A1—endocrine gland—polycystic ovary syndrome	0.000252	0.00244	CbGeAlD
Erlotinib—Vomiting—Metformin—polycystic ovary syndrome	0.000249	0.0106	CcSEcCtD
Erlotinib—Rash—Metformin—polycystic ovary syndrome	0.000247	0.0105	CcSEcCtD
Erlotinib—Dermatitis—Metformin—polycystic ovary syndrome	0.000247	0.0105	CcSEcCtD
Erlotinib—CYP3A5—endocrine gland—polycystic ovary syndrome	0.000247	0.00239	CbGeAlD
Erlotinib—Headache—Metformin—polycystic ovary syndrome	0.000245	0.0104	CcSEcCtD
Erlotinib—Nausea—Metformin—polycystic ovary syndrome	0.000233	0.0099	CcSEcCtD
Erlotinib—ABCB1—adrenal cortex—polycystic ovary syndrome	0.000209	0.00203	CbGeAlD
Erlotinib—CYP2D6—female gonad—polycystic ovary syndrome	0.000196	0.0019	CbGeAlD
Erlotinib—ABCB1—endometrium—polycystic ovary syndrome	0.000187	0.00181	CbGeAlD
Erlotinib—CYP3A4—endocrine gland—polycystic ovary syndrome	0.000185	0.00179	CbGeAlD
Erlotinib—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000182	0.00176	CbGeAlD
Erlotinib—ABCB1—uterus—polycystic ovary syndrome	0.000172	0.00167	CbGeAlD
Erlotinib—ABCB1—pituitary gland—polycystic ovary syndrome	0.000169	0.00164	CbGeAlD
Erlotinib—ABCB1—adipose tissue—polycystic ovary syndrome	0.000168	0.00163	CbGeAlD
Erlotinib—ABCB1—adrenal gland—polycystic ovary syndrome	0.000151	0.00146	CbGeAlD
Erlotinib—ABCB1—female gonad—polycystic ovary syndrome	0.000141	0.00136	CbGeAlD
Erlotinib—ABCB1—vagina—polycystic ovary syndrome	0.00014	0.00136	CbGeAlD
Erlotinib—ABCB1—endocrine gland—polycystic ovary syndrome	0.000131	0.00127	CbGeAlD
Erlotinib—CYP1A2—Metabolism—SRD5A1—polycystic ovary syndrome	8.07e-06	6.54e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—YAP1—polycystic ovary syndrome	8.06e-06	6.53e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—VEGFA—polycystic ovary syndrome	8.05e-06	6.52e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—VEGFA—polycystic ovary syndrome	7.98e-06	6.47e-05	CbGpPWpGaD
Erlotinib—MKNK1—Disease—IL6—polycystic ovary syndrome	7.95e-06	6.44e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IRS1—polycystic ovary syndrome	7.94e-06	6.44e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—RRM2—polycystic ovary syndrome	7.9e-06	6.4e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—POMC—polycystic ovary syndrome	7.88e-06	6.38e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—NCOR1—polycystic ovary syndrome	7.87e-06	6.38e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CYP19A1—polycystic ovary syndrome	7.85e-06	6.36e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKR1C2—polycystic ovary syndrome	7.84e-06	6.35e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TEAD2—polycystic ovary syndrome	7.84e-06	6.35e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—INS—polycystic ovary syndrome	7.83e-06	6.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ATF1—polycystic ovary syndrome	7.8e-06	6.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IRS2—polycystic ovary syndrome	7.78e-06	6.3e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CRP—polycystic ovary syndrome	7.78e-06	6.3e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NAMPT—polycystic ovary syndrome	7.74e-06	6.27e-05	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—IL6—polycystic ovary syndrome	7.74e-06	6.27e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	7.73e-06	6.26e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GNAS—polycystic ovary syndrome	7.7e-06	6.24e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—STAR—polycystic ovary syndrome	7.7e-06	6.24e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP11A1—polycystic ovary syndrome	7.65e-06	6.2e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—YAP1—polycystic ovary syndrome	7.61e-06	6.17e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—polycystic ovary syndrome	7.61e-06	6.17e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TCF7L2—polycystic ovary syndrome	7.61e-06	6.16e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IGF1—polycystic ovary syndrome	7.58e-06	6.14e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT2—polycystic ovary syndrome	7.57e-06	6.13e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MTHFR—polycystic ovary syndrome	7.55e-06	6.11e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—LHB—polycystic ovary syndrome	7.48e-06	6.06e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—SULT2A1—polycystic ovary syndrome	7.48e-06	6.06e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CYP1A1—polycystic ovary syndrome	7.46e-06	6.04e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SULT2A1—polycystic ovary syndrome	7.43e-06	6.02e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT2—polycystic ovary syndrome	7.35e-06	5.96e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—NCOR1—polycystic ovary syndrome	7.34e-06	5.95e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NAMPT—polycystic ovary syndrome	7.31e-06	5.93e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—HSD3B2—polycystic ovary syndrome	7.31e-06	5.92e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	7.27e-06	5.89e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—RRM2—polycystic ovary syndrome	7.24e-06	5.87e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CYP11A1—polycystic ovary syndrome	7.22e-06	5.85e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKR1C3—polycystic ovary syndrome	7.22e-06	5.85e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—RRM2—polycystic ovary syndrome	7.2e-06	5.83e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NGFR—polycystic ovary syndrome	7.2e-06	5.83e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SERPINE1—polycystic ovary syndrome	7.19e-06	5.83e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IRS2—polycystic ovary syndrome	7.18e-06	5.82e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	7.17e-06	5.81e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—POMC—polycystic ovary syndrome	7.15e-06	5.8e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PRL—polycystic ovary syndrome	7.13e-06	5.78e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP17A1—polycystic ovary syndrome	7.11e-06	5.76e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—IL6—polycystic ovary syndrome	7.11e-06	5.76e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKR1C1—polycystic ovary syndrome	7.08e-06	5.74e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	7.05e-06	5.71e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GNAS—polycystic ovary syndrome	7.01e-06	5.68e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—YAP1—polycystic ovary syndrome	6.98e-06	5.66e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CYP1A1—polycystic ovary syndrome	6.96e-06	5.64e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—MTHFR—polycystic ovary syndrome	6.95e-06	5.63e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—YAP1—polycystic ovary syndrome	6.94e-06	5.62e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IGF1—polycystic ovary syndrome	6.91e-06	5.6e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT2—polycystic ovary syndrome	6.9e-06	5.59e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	6.89e-06	5.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT2—polycystic ovary syndrome	6.88e-06	5.57e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HMMR—polycystic ovary syndrome	6.86e-06	5.56e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKR1C3—polycystic ovary syndrome	6.82e-06	5.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IRS1—polycystic ovary syndrome	6.79e-06	5.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ADRB2—polycystic ovary syndrome	6.77e-06	5.49e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CYP17A1—polycystic ovary syndrome	6.72e-06	5.44e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NAMPT—polycystic ovary syndrome	6.71e-06	5.43e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—NCOR1—polycystic ovary syndrome	6.68e-06	5.41e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	6.67e-06	5.4e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NAMPT—polycystic ovary syndrome	6.67e-06	5.4e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	6.67e-06	5.4e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	6.63e-06	5.37e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP11A1—polycystic ovary syndrome	6.62e-06	5.37e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP11A1—polycystic ovary syndrome	6.58e-06	5.34e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	6.57e-06	5.33e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	6.57e-06	5.32e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—SERPINE1—polycystic ovary syndrome	6.56e-06	5.32e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HSD3B1—polycystic ovary syndrome	6.55e-06	5.3e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	6.54e-06	5.3e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SULT2A1—polycystic ovary syndrome	6.51e-06	5.28e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL6—polycystic ovary syndrome	6.49e-06	5.26e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—MTHFR—polycystic ovary syndrome	6.48e-06	5.25e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—polycystic ovary syndrome	6.47e-06	5.24e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—IL6—polycystic ovary syndrome	6.46e-06	5.24e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—BCL2—polycystic ovary syndrome	6.42e-06	5.2e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CYP1A1—polycystic ovary syndrome	6.33e-06	5.13e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—RRM2—polycystic ovary syndrome	6.31e-06	5.11e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT2—polycystic ovary syndrome	6.28e-06	5.09e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GNAS—polycystic ovary syndrome	6.28e-06	5.09e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IRS1—polycystic ovary syndrome	6.27e-06	5.08e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKR1C3—polycystic ovary syndrome	6.25e-06	5.07e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	6.23e-06	5.05e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKR1C3—polycystic ovary syndrome	6.22e-06	5.04e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP17A1—polycystic ovary syndrome	6.16e-06	4.99e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TH—polycystic ovary syndrome	6.15e-06	4.98e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	6.14e-06	4.97e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—polycystic ovary syndrome	6.13e-06	4.97e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP17A1—polycystic ovary syndrome	6.12e-06	4.96e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—YAP1—polycystic ovary syndrome	6.08e-06	4.93e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.07e-06	4.92e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—INS—polycystic ovary syndrome	6e-06	4.86e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—SLC2A4—polycystic ovary syndrome	5.98e-06	4.85e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NCOR1—polycystic ovary syndrome	5.98e-06	4.85e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—LHB—polycystic ovary syndrome	5.97e-06	4.84e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	5.94e-06	4.82e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	5.94e-06	4.81e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—MTHFR—polycystic ovary syndrome	5.9e-06	4.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NRG1—polycystic ovary syndrome	5.87e-06	4.76e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NAMPT—polycystic ovary syndrome	5.84e-06	4.73e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HSD3B2—polycystic ovary syndrome	5.83e-06	4.73e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TH—polycystic ovary syndrome	5.81e-06	4.71e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT2—polycystic ovary syndrome	5.8e-06	4.7e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP11A1—polycystic ovary syndrome	5.77e-06	4.68e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	5.73e-06	4.64e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—IL6—polycystic ovary syndrome	5.71e-06	4.62e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—SLC2A4—polycystic ovary syndrome	5.65e-06	4.58e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKR1C1—polycystic ovary syndrome	5.65e-06	4.58e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PPARG—polycystic ovary syndrome	5.64e-06	4.57e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP19A1—polycystic ovary syndrome	5.63e-06	4.56e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL6—polycystic ovary syndrome	5.57e-06	4.51e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—POMC—polycystic ovary syndrome	5.56e-06	4.51e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—INS—polycystic ovary syndrome	5.53e-06	4.48e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—IL6—polycystic ovary syndrome	5.52e-06	4.47e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—SERPINE1—polycystic ovary syndrome	5.51e-06	4.47e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	5.51e-06	4.46e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—BCL2—polycystic ovary syndrome	5.49e-06	4.45e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKR1C3—polycystic ovary syndrome	5.45e-06	4.42e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	5.44e-06	4.41e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP17A1—polycystic ovary syndrome	5.36e-06	4.35e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TH—polycystic ovary syndrome	5.33e-06	4.32e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CYP19A1—polycystic ovary syndrome	5.31e-06	4.31e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TH—polycystic ovary syndrome	5.3e-06	4.29e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	5.29e-06	4.29e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PPARG—polycystic ovary syndrome	5.26e-06	4.26e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SULT2A1—polycystic ovary syndrome	5.2e-06	4.21e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—POMC—polycystic ovary syndrome	5.19e-06	4.2e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—SLC2A4—polycystic ovary syndrome	5.18e-06	4.2e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—INS—polycystic ovary syndrome	5.16e-06	4.18e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SLC2A4—polycystic ovary syndrome	5.15e-06	4.18e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	5.13e-06	4.16e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	5.05e-06	4.1e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	5.05e-06	4.09e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—RRM2—polycystic ovary syndrome	5.04e-06	4.08e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IRS2—polycystic ovary syndrome	5.03e-06	4.07e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GNAS—polycystic ovary syndrome	5.02e-06	4.07e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.95e-06	4.01e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—LEP—polycystic ovary syndrome	4.92e-06	3.99e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—IL6—polycystic ovary syndrome	4.88e-06	3.95e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP19A1—polycystic ovary syndrome	4.87e-06	3.95e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—YAP1—polycystic ovary syndrome	4.85e-06	3.93e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP19A1—polycystic ovary syndrome	4.84e-06	3.93e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PPARG—polycystic ovary syndrome	4.78e-06	3.88e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NCOR1—polycystic ovary syndrome	4.78e-06	3.88e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GNAS—polycystic ovary syndrome	4.74e-06	3.84e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—POMC—polycystic ovary syndrome	4.72e-06	3.82e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—INS—polycystic ovary syndrome	4.69e-06	3.8e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NAMPT—polycystic ovary syndrome	4.66e-06	3.78e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TH—polycystic ovary syndrome	4.64e-06	3.76e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	4.64e-06	3.76e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	4.61e-06	3.73e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP11A1—polycystic ovary syndrome	4.61e-06	3.73e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	4.57e-06	3.71e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CYP1A1—polycystic ovary syndrome	4.53e-06	3.67e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NCOR1—polycystic ovary syndrome	4.52e-06	3.66e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SLC2A4—polycystic ovary syndrome	4.51e-06	3.66e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—polycystic ovary syndrome	4.51e-06	3.66e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	4.5e-06	3.65e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IRS1—polycystic ovary syndrome	4.39e-06	3.56e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TH—polycystic ovary syndrome	4.37e-06	3.54e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	4.36e-06	3.53e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKR1C3—polycystic ovary syndrome	4.35e-06	3.52e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GNAS—polycystic ovary syndrome	4.35e-06	3.52e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GNAS—polycystic ovary syndrome	4.32e-06	3.5e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP17A1—polycystic ovary syndrome	4.28e-06	3.47e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	4.25e-06	3.45e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP19A1—polycystic ovary syndrome	4.24e-06	3.44e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MTHFR—polycystic ovary syndrome	4.23e-06	3.43e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—POMC—polycystic ovary syndrome	4.23e-06	3.42e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—INS—polycystic ovary syndrome	4.2e-06	3.41e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—polycystic ovary syndrome	4.2e-06	3.4e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NCOR1—polycystic ovary syndrome	4.14e-06	3.36e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NCOR1—polycystic ovary syndrome	4.12e-06	3.34e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF1—polycystic ovary syndrome	4.07e-06	3.29e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT2—polycystic ovary syndrome	4.06e-06	3.29e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	4.01e-06	3.25e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	4e-06	3.24e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MTHFR—polycystic ovary syndrome	3.99e-06	3.24e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CYP1A1—polycystic ovary syndrome	3.93e-06	3.18e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CYP1A1—polycystic ovary syndrome	3.9e-06	3.16e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	3.89e-06	3.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.86e-06	3.13e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GNAS—polycystic ovary syndrome	3.79e-06	3.07e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	3.75e-06	3.04e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TH—polycystic ovary syndrome	3.7e-06	3e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTHFR—polycystic ovary syndrome	3.66e-06	2.97e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTHFR—polycystic ovary syndrome	3.64e-06	2.95e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NCOR1—polycystic ovary syndrome	3.61e-06	2.92e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC2A4—polycystic ovary syndrome	3.6e-06	2.92e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	3.6e-06	2.92e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	3.57e-06	2.89e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	3.55e-06	2.88e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PPARG—polycystic ovary syndrome	3.43e-06	2.78e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—polycystic ovary syndrome	3.42e-06	2.77e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CYP1A1—polycystic ovary syndrome	3.42e-06	2.77e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	3.4e-06	2.76e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP19A1—polycystic ovary syndrome	3.39e-06	2.75e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—POMC—polycystic ovary syndrome	3.38e-06	2.74e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—INS—polycystic ovary syndrome	3.36e-06	2.72e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	3.36e-06	2.72e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—polycystic ovary syndrome	3.32e-06	2.69e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	3.3e-06	2.68e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPARG—polycystic ovary syndrome	3.24e-06	2.62e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	3.22e-06	2.61e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—POMC—polycystic ovary syndrome	3.19e-06	2.59e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTHFR—polycystic ovary syndrome	3.19e-06	2.58e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—INS—polycystic ovary syndrome	3.18e-06	2.57e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—polycystic ovary syndrome	3.11e-06	2.52e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GNAS—polycystic ovary syndrome	3.02e-06	2.45e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	3.01e-06	2.44e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPARG—polycystic ovary syndrome	2.97e-06	2.41e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPARG—polycystic ovary syndrome	2.95e-06	2.39e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—POMC—polycystic ovary syndrome	2.93e-06	2.37e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—INS—polycystic ovary syndrome	2.91e-06	2.36e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—POMC—polycystic ovary syndrome	2.91e-06	2.36e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—INS—polycystic ovary syndrome	2.9e-06	2.35e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NCOR1—polycystic ovary syndrome	2.88e-06	2.33e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TH—polycystic ovary syndrome	2.86e-06	2.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—polycystic ovary syndrome	2.84e-06	2.3e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	2.78e-06	2.25e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CYP1A1—polycystic ovary syndrome	2.73e-06	2.21e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.66e-06	2.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—polycystic ovary syndrome	2.62e-06	2.13e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	2.62e-06	2.12e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARG—polycystic ovary syndrome	2.59e-06	2.1e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—POMC—polycystic ovary syndrome	2.55e-06	2.07e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTHFR—polycystic ovary syndrome	2.55e-06	2.06e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—INS—polycystic ovary syndrome	2.54e-06	2.06e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	2.44e-06	1.98e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	2.4e-06	1.95e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—INS—polycystic ovary syndrome	2.39e-06	1.94e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	2.33e-06	1.89e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	2.22e-06	1.8e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	2.11e-06	1.71e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARG—polycystic ovary syndrome	2.06e-06	1.67e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—POMC—polycystic ovary syndrome	2.04e-06	1.65e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—INS—polycystic ovary syndrome	2.03e-06	1.64e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	1.97e-06	1.59e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—polycystic ovary syndrome	1.84e-06	1.49e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	1.59e-06	1.29e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	1.57e-06	1.27e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—INS—polycystic ovary syndrome	1.56e-06	1.27e-05	CbGpPWpGaD
